Chengdu Jinweike Biotechnology
People coming together to achieve a common goal.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | CNY20.0m | Series A | |
| Total Funding | 000k | ||
Established on December 22, 2017, the company specializes in biotechnology research and development, focusing on the preparation and marketing of biopharmaceuticals, experimental reagents, and medical devices. Operating within the biopharmaceutical market, it serves clients engaged in basic research using AAV carriers. The business model revolves around providing high-quality AAV virus formulations, supported by detailed quality control reports, including purity and drop trip metrics. Revenue is generated through the sale of these formulations and related services. The company boasts a 600 flat GMP level workshop and a fully developed AAV scale preparation and quality control technology platform, catering to the clinical declaration needs of AAV genetic products. The AAV Genetic Medicine Research Centre is set to enhance its operational capabilities. Key personnel include Dr. Yang Yang, who has contributed to significant research published in Science Advances.